ENVALITH
エムスリー株式会社 logo

M3, Inc.

2413・Prime Market・Services

Official website
エムスリー株式会社 logo
M3, Inc.2413

Business

M3, Inc. operates a professional platform for healthcare providers centered on "m3.com," with over 350,000 registered physicians in Japan and over 7 million globally. The company operates across the entire healthcare value chain, spanning marketing support for pharmaceutical companies (including the MR-kun family of services), clinical development support (CRO/SMO), staffing services for healthcare professionals, support for medical institution operations, provision of CS sets for hospitalized patients, and overseas medical information services. Its major customers span a wide range, including pharmaceutical companies, medical institutions, healthcare professionals, hospitalized patients, and nursing care facility users, with revenue for FY2026 (ending March 2026) reaching ¥351,363 million.

Business Model

The company attracts doctors and healthcare professionals to "m3.com" free of charge, and leverages this member base to provide fee-based services such as marketing support and research services for pharmaceutical companies, DX solutions for medical institutions, staffing services for healthcare professionals, and clinical development support (CRO/SMO). The scale and quality of its member base serve as a source of competitive advantage, and the company pursues intra-group ecosystem synergies while expanding its business scope through M&A both domestically and internationally.

Company Strengths

"m3.com" is one of Japan's largest specialized websites for healthcare professionals, boasting over 350,000 registered physician members domestically (as of May 2026). This member base forms the foundation of competitive advantage across multiple businesses, including pharmaceutical marketing support, research, recruiting, and clinical trial subject recruitment, creating an entry barrier that competitors cannot easily replicate in the short term.

In FY2026 (ending March 2026), the Medical Platform segment achieved revenue of ¥107,830 million, segment profit of ¥35,918 million, and a profit margin of 33.3%. High-value-added services such as pharmaceutical marketing support and medical DX have driven revenue, functioning as a high-profitability core segment that accounts for the majority of the group's overall profit.

The company holds a physician panel of over 7 million members across Japan, the United States, Europe, China, South Korea, India, and other regions, with overseas segment revenue of ¥86,921 million recorded in FY2026 (ending March 2026). In Europe, VIDAL Group operates a pharmaceutical information database and SaaS-based electronic medical records; in North America, the company supports clinical trials; and in Asia, it is expanding operations centered on India and South Korea, achieving revenue diversification through geographic dispersion.

ENVALITH's Perspective

While revenue has maintained an expansionary trend since FY2022 (ending March 2022), operating profit had declined for three consecutive periods after peaking at ¥95,141 million in FY2022 (ending March 2022). In FY2026 (ending March 2026), operating profit reached ¥73,547 million (up 16.8% year on year), marking the first increase in four periods. This was supported by a smaller drag from the falloff of COVID-19-related projects, improved profitability in Evidence Solutions, and expanded profitability in Patient Solutions. However, the operating profit margin stood at 20.9%, a substantial decline from 45.7% in FY2022 (ending March 2022), and a return to peak levels is expected to take time.

Due to a series of acquisitions including Elan, Noacontsern, and iWell, goodwill stands at ¥124,087 million and intangible assets at ¥99,203 million, together accounting for 35.1% of total assets of ¥637,396 million. In FY2026 (ending March 2026), the company recorded impairment losses of ¥6,677 million (up from ¥2,077 million in the previous period), related to the North American clinical trial business and the UK physician career business, among others. Overseas operations have also seen negative effects from vaccine-related policy shifts in the US, and impairment risk is expected to persist going forward. While FY2027 (ending March 2027) is expected to benefit from the falloff of these impairment losses, additional risk from new M&A activity cannot be ruled out.

Following the consolidation of Elan as a subsidiary, Patient Solutions expanded rapidly, with revenue of ¥56,877 million in FY2026 (ending March 2026), up 159.5% year on year, contributing significantly to the group's overall revenue growth. However, segment profit margin remained low at 4.7%, weighing on the group's overall profitability. In FY2027 (ending March 2027), the segment is expected to achieve both revenue and profit growth through new CS set contract acquisitions and the generation of group synergies, with the pace of margin improvement likely to be a focus for investors. As an external factor, the aging population and rising number of hospitalized patients represent a favorable market tailwind.

Growth Strategy

Multi-pronged strategy encompassing enhancement of the m3.com platform value, utilization of M&A, overseas expansion, and creation of group synergies

Strengthening and promoting drug-related issue-solving proposals that capture the essential DX needs of pharmaceutical companies. Aiming to increase the added value of marketing support for pharmaceutical companies by combining technology, including AI, with diverse data assets. In FY2026 (ending March 2026), Medical Platform achieved revenue growth of 17.8% year on year, and revenue and profit growth is also expected in FY2027 (ending March 2027).

Providing medical institutions with a variety of medical AI solutions centered on electronic medical records and diagnostic support systems equipped with AI functions, as well as the image diagnosis support field. Also developing Third-Party Succession Support for Practicing Physicians leveraging the member base of "m3.com". Aiming to capture DX needs at medical institutions and continue the growth of Medical Platform.

Starting from the consolidation of Elan as a subsidiary (October 2024), promoting an increase in the number of users through new CS Set (Care Support Set) contract acquisitions, while actively developing service development and cross-selling as group synergy creation. In FY2026 (ending March 2026), revenue expanded rapidly to ¥56,877 million. Revenue and profit growth is expected in FY2027 (ending March 2027).

Leveraging a global physician registration base of over 7 million, promoting expansion by combining organic growth with contributions from acquisitions, centered on Europe and Asia. In FY2026 (ending March 2026), Europe and other regions delivered solid results. In the North America Clinical Trial Support Services business, a negative impact related to vaccines emerged due to a shift in US policy, but revenue and profit growth is expected in FY2027 (ending March 2027), aided by the effect of the disappearance of impairment losses.

In FY2026 (ending March 2026), a year-end dividend of ¥22 (annual dividend of ¥22) was implemented, with total dividends paid of ¥14,683 million. In addition, ¥20,000 million of treasury shares were acquired during FY2026 (ending March 2026). By resolution of the Board of Directors on May 1, 2026, a share buyback of up to 20 million shares and ¥20.0 billion was resolved, to be executed by April 30, 2027. The dividend forecast has not yet been determined at this time.

Last updated: July 19, 2026